Back to Immunity
SupplementPreliminary evidenceImmunity

Guggul (Commiphora mukul)

Ayurvedic resin traditionally for lipid management, early enthusiasm dampened by the Szapary 2003 JAMA RCT in US adults, which was null.

Why

Guggul (Commiphora mukul resin) has been used in Ayurveda for over 2,500 years for lipid and obesity-related complaints. Early Indian RCTs reported substantial cholesterol reductions, but the larger Szapary 2003 JAMA RCT in US adults was null, fasting LDL actually rose modestly in the guggul groups. Likely explanation: differences in baseline diet (Indian vegetarian vs US Western) affecting bile-acid recycling. Used clinically in India; not widely recommended in Western practice as a result.

How it works

Guggulsterones are farnesoid X receptor (FXR) antagonists, reduce hepatic LDL receptor expression in some preclinical models. Mechanism appears dietary-context-dependent, modulation of bile-acid recycling matters.

Expected onset · Lipid effects over 8–12 weeks (when present)

How to take

Dosage

Standardised guggulipid (2.5% guggulsterones): 500 mg three times daily. Traditional resin: 1–2 g/day.

Timing

Divided 2–3 times daily with meals

On the label

Standardised guggulipid (Commiphora mukul resin extract) with stated guggulsterone content (2.5–6%).

Ideal for

Adults exploring Ayurvedic lipid-management options under specialist guidance, with awareness that effect may be diet-context-dependent.

Safety

Mild gastrointestinal upset, rash. Hypothyroidism: theoretical concern of additive thyroid hormone metabolism. Coordinate with prescriber. CYP3A4 induction, interactions with statins, calcium channel blockers, propranolol. Pregnancy and breastfeeding: avoid.

Evidence

At a glance

Szapary 2003 JAMA RCT (n=103 US adults with dyslipidaemia): guggulipid 1,000 mg or 2,000 mg three times daily for 8 weeks did not reduce LDL, and LDL actually rose modestly. Earlier Indian trials reported reductions; likely diet-context dependent. Preliminary, RCTs exist in non-tier-1 journals but are small or short-duration. No Cochrane review, EMA monograph or EFSA-authorised claim covers the indication. This is a case where honest framing means acknowledging that Western replication has been disappointing.

Limitations

Preliminary, RCTs exist in non-tier-1 journals but are small or short-duration. No Cochrane review, EMA monograph or EFSA-authorised claim covers the indication.

Where to get it

Shop Guggul (Commiphora mukul) on Amazon

Sponsored · As an Amazon Associate, Healicus earns from qualifying purchases.